Company patents
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. exhibits a focused patent strategy within pharma_biotech, with a surprising recent shift as its largest category, Heterocyclic Compounds, saw a 31.2% decline in 2024 and an 18.2% decline so far in 2026, while Pharmaceutical Preparations emerged as a rapidly growing focus with a 100.0% increase in 2025, reaching 52.1% of its portfolio.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
73 US filings (since 2023) · 5 categories · 8 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Patents
Showing 1-9 of 9
API Solid Form Engineering